Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
VKTX has four catalysts on tap in H1'24, with data from the company's weight loss drug, VK2735, looking set to produce data in Q1'24. VKTX has $376M in cash, cash equivalents and short-term investments, meaning the company is funded for years to come. Viking Therapeutics' ( NASDAQ: VKTX ) most advanced pipeline candidate is VK2809, a drug for non-alcoholic steatohepatitis (NASH). A lot of the excitement surrounding VKTX right now, however, relates to its obesity drug, VK2735 (the drug also has potential in various metabolic disorders including diabetes and NASH). Incretin developers are rallying right now On December 4, Roche ( OTCQX:RHHBY ) announced a merger agreement to acquire Carmot Therapeutics (which was about to IPO) for $2.7B in cash, and up to $400M in milestones. The deal sees RHHBY get a hold of Carmot's pipeline of incretins, including the phase 2 ready drug CT-388, which is an agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polype
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain [Seeking Alpha]Seeking Alpha
- Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program [Yahoo! Finance]Yahoo! Finance
- Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (VKTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi-Year Run [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website